Filing Flows › Sarepta Therapeutics (SRPT) › Q3 2026 › vs Q3 2025
Sarepta Therapeutics (SRPT) Q3 2026 vs Q3 2025 (year over year)
Sarepta Therapeutics's revenue fell $18.0M (-5%) from $399M in Q3 2025 to $381M in Q3 2026. The biggest changes: Elevidys −$48.0M (-37%); Other revenues +$28.3M (+96%); Pmo Products +$1.8M (+0.7%).
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 15.0% | -9.4% | +24.4 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Pmo Products | $240M | $239M | $1.8M | +0.7% |
| Elevidys | $83.5M | $131M | −$48.0M | -37% |
| Other revenues | $57.6M | $29.3M | $28.3M | +96% |
| Revenue | $381M | $399M | −$18.0M | -5% |
| Net loss | $28.5M | $50.6M | −$22.1M | -44% |
| Costs & expenses | $410M | $503M | −$92.9M | -18% |
| Operating costs | $390M | $503M | −$112M | -22% |
| Interest & other, net | $16.7M | −$38.7M | $55.4M | — |
| Income tax | $2.7M | −$14.1M | $16.8M | — |
| Research & development | $82.5M | $219M | −$136M | -62% |
| SG&A | $119M | $91.9M | $26.7M | +29% |
| Other operating costs | $189M | $11.9M | $177M | 16× |
| Operating cash sources | $88.4M | $36.0M | $52.4M | +146% |
| Depreciation & amortization | $5.9M | $18.4M | −$12.6M | -68% |
| Share-based compensation | $26.7M | $14.9M | $11.8M | +79% |
| Working capital & other | $55.8M | $2.6M | $53.2M | 21× |
| Net loss absorbed | $28.5M | $50.6M | −$22.1M | -44% |
| Operating cash flow | $60.0M | −$14.6M | $74.6M | — |
| Free cash flow (OCF − capex) | $57.0M | −$37.5M | $94.6M | — |
| Capital expenditures | $2.9M | $22.9M | −$20.0M | -87% |
Questions
How much did Sarepta Therapeutics's revenue grow year over year in Q3 2026?
Sarepta Therapeutics's revenue fell $18.0M (-5%) from $399M in Q3 2025 to $381M in Q3 2026.
What drove Sarepta Therapeutics's revenue change in Q3 2026?
Elevidys −$48.0M (-37%); Other revenues +$28.3M (+96%); Pmo Products +$1.8M (+0.7%).